Qualitative and quantitative composition Each hard capsule contains atomoxetine hydrochloride equivalent to 10mg, 18mg, 25mg, 40mg, 60mg, 80mg or mg of atomoxetine.
For the full list of excipients, see Section 6. Pharmaceutical form Capsule, hard. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Diagnosis strattera dosage for child normal be made solely on the presence of one or more symptoms of ADHD. Additional information for strattera dosage safe use of this product: A strattera dosage for child normal treatment programme typically includes psychological, educational and social measures and is aimed at stabilising patients with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG.
Learning may or may not be impaired. Pharmacological treatment is not indicated in all patients with this syndrome and the decision to use the drug must child normal based strattera dosage for child normal dosage for a very thorough assessment of the severity of the patient's symptoms and impairment in relation to the patient's age and the persistence of symptoms.
Patients who do not achieve a satisfactory clinical response tolerability [e.
Dosing of paediatric population up to 70 kg Body Weight: The initial dose should be maintained for a minimum of 7 days prior to upward dose titration according to strattera dosage for child normal response and tolerability.
The recommended maintenance dose is approximately 1. No additional benefit has /ingredients-in-propranolol-infants-side-effects.html demonstrated for doses higher than 1. The safety of single doses over 1.
In some cases it might be appropriate to continue treatment into adulthood. Dosing of paediatric child normal over 70 kg Body Weight: The recommended maintenance strattera dosage for child normal is 80mg. No additional benefit has been demonstrated for doses higher than 80 mg. The maximum recommended total daily dose is mg.
The safety of single doses over mg and total daily doses above mg have not been systematically child normal. The recommended maintenance daily dose is 80mg to mg. Prior to prescribing it is necessary to take an appropriate medical history and conduct a baseline evaluation of a patient's cardiovascular status, including blood pressure and child normal rate see sections 4. Cardiovascular status should child normal regularly monitored with blood pressure and pulse child normal after each strattera dosage for of dose and then at least every 6 months.
For paediatric patients the child normal of a centile chart is recommended. strattera dosage for child normal
For adults, current reference guidelines for hypertension should be followed. In the study programme no distinct withdrawal symptoms have been described. In cases of significant adverse effects, atomoxetine may be stopped abruptly; otherwise the strattera dosage for child normal may be tapered off over a suitable time period. Child normal of the need for continued therapy beyond 1 year should be performed, particularly when the patient has reached a stable and satisfactory response.
Atomoxetine may exacerbate hypertension in patients with end-stage renal disease see section 5. Patients with this genotype have a several-fold higher strattera dosage for child normal to atomoxetine when compared to patients with a functional enzyme. Poor metabolisers are therefore at higher risk of adverse events see section 4. For patients with a known poor metaboliser genotype, a lower starting dose and slower up titration of the dose may be considered.
strattera dosage for child normal dosage for child normal use of atomoxetine in patients over 65 years of age has not been systematically evaluated. Paediatric population under six years of age: Strattera can be administered with or without food. Atomoxetine should not be used in combination with child normal oxidase inhibitors MAOI. Atomoxetine should not be used within a minimum of 2 weeks after discontinuing therapy with MAOI.
Treatment with MAOI should not be initiated within 2 weeks after for child normal atomoxetine. Atomoxetine should not be used in patients with narrow-angle glaucoma, as in clinical trials the use of atomoxetine was associated strattera dosage for child normal an increased incidence of mydriasis.
Atomoxetine should not be used child normal patients with severe cardiovascular or cerebrovascular disorders see section 4. Severe cardiovascular disorders may include severe hypertension, heart failure, arterial occlusive strattera dosage for child normal, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies disorders caused by the dysfunction of ion channels.
Severe cerebrovascular disorders may include cerebral aneurysm or stroke. Atomoxetine should not be used in patients with pheochromocytoma or a history of pheochromocytoma see section 4. Suicide-related behaviour suicide attempts and suicidal ideation has been reported in patients treated with atomoxetine.
In double-blind clinical trials, strattera dosage for child normal behaviours were uncommon, but strattera dosage for /robaxin-icd-10.html observed among children and adolescents treated with /tylenol-or-aleve-for-headache-effects.html compared to those treated with placebo, where there were no events. In adult double-blind clinical trials there was no difference in the frequency of suicide-related behaviour between atomoxetine and placebo.
2018 ©